The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing its proprietary ReSOLVE™ platform to discover and ...

A first healthy adults group has been dosed in an early clinical trial of an oral and myelin-protective treatment for all types of MS.

Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an ...

Arcellx (NASDAQ:ACLX) announced an update for its Phase 3 iMMagine-3 study and plans to present Phase 1 and 2 data for its therapy candidate anito-cel for the treatment of multiple myeloma. The ...

Ichnos Glenmark Innovation's cancer drug ISB 2001 shows promising results in Phase 1 trial, to be presented at ASH.

MindMed is poised for significant developments with MM-120 in upcoming trials. Discover why monitoring MNMD stock is ...

With a new way to break the blood-brain barrier, an Aliada Therapeutics deal could give the North Chicago drugmaker's ...

ImmunityBio (IBRX) stock surged as the company announced dosing initiation in a Phase 1 trial for CD19 t-haNK cell therapy in ...

NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignancies Low molecular weight of NM32 ...

TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal ...

Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of ...